Conavi's PR Push Is for Investors, Not Cardiologists

Conavi Medical just spent about C$230,000 to make its stock more visible. The money bought two contracts revealed on September 4: a C$98,000 media-services deal with Market One, and a US$100,000 digital-marketing deal with Winning Media. The stated purpose is to "elevate" the company's market profile. Read what those firms actually sell — financial content distribution, influencer outreach, podcast placements, appearances on BNN Bloomberg — and it's clear who the marketing is aimed at. It is not aimed at cardiologists. Winning Media is not an innocent bystander either: it holds 705,100 Conavi shares, so it profits from a rising profile the same way any shareholder does.

That distinction matters, because Conavi's real product is for cardiologists. The company makes the Novasight Hybrid, a catheter that images the inside of a coronary artery two ways at once — intravascular ultrasound and optical coherence tomography, in a single pullback. It is the first co-registered, co-aligned IVUS-OCT platform on the market, and it guides the common procedure where a stent is placed. The FDA cleared the next-generation system in April 2026, and the company says the first U.S. clinical placement should come in the second half of this year.

So here is a device company at the edge of a genuine commercial launch, and its newest marketing dollars are going to influencers and financial newsletters rather than to the people who decide which catheter a hospital buys. No appearance on BNN Bloomberg sells a single unit to a cath lab. That spend is for the shareholder, not the customer.

The numbers explain why. Conavi is, for practical purposes, pre-revenue: fiscal Q3 revenue was C$0.1 million, mostly licensing. The quarter's net loss was C$6.3 million, and research and development ate C$4.4 million of it. Cash had fallen to C$0.9 million by June 30. Two weeks ago the company closed a US$10 million public offering — on the order of two quarters of the recent burn rate, if that. This is a company whose survival depends on the next financing, and a louder market profile is how a pre-revenue stock gets the next financing at a better price. The promotional engine is there to keep the balance sheet alive between raises, not to build product demand.

Keep Your Identity Small, the way the thinking goes. Strip away the "commercial-stage medical device company" label and ask what is actually happening. A product nobody has yet paid for needs money. The money comes from public investors who buy on visibility. So the company buys visibility. It is a rational loop, and it is the same loop that runs through most TSX Venture microcaps.

The trap for an investor is mistaking the loop for product traction. Conavi has a real reason to exist — hybrid IVUS-OCT could genuinely be better than the single-modality systems from Philips, Boston Scientific, and Abbott that dominate a market the company sizes above US$1 billion. And U.S. guidelines now put intravascular imaging at a Class 1A recommendation, which is a tailwind no amount of marketing could buy. None of that is hype.

But demand here will be demonstrated by behavior, not by profile. The moment of truth is whether the first U.S. placements turn into paid, repeat catheter sales — whether hospitals reorder because the hybrid makes a procedure go better. That is the test the two PR contracts cannot pass for the company. Watch the placements, and watch whether they produce recurring revenue and shrinking dilution. If the placements arrive but the catheter pull-through doesn't, you are watching a marketing company that happens to make a clever device, funded by whoever is left holding the stock.

The marketing deal itself is small money and no surprise. The useful discovery is what it reveals about the customer Conavi is actually serving right now: the market that funds its next quarter, not the physician who will eventually buy its catheter. Until the product starts converting to payment, an elevated profile is a way to raise capital, and every raise dilutes what an early buyer owns. The question worth holding onto is which of those two customers shows up first.